Emotional Intelligence Ventures Reg A Raises $ 20 Million, Company Continues Research into Transdermal Delivery of Psylocibin, Plans to Launch Nutraceutical Mushroom Supplements | New
MIAMI – (BUSINESS WIRE) – October 19, 2021–
Emotional intelligence companies, led by a renowned investor and executive David nikzad, are happy to report that their Settlement A increase is currently $ 20,114,949, with more investors arriving daily. Ultimately, they’re looking to raise a maximum of $ 49,999,999 and think it’s a very achievable goal. A Settlement A offering allows retail investors to invest in pre-public and private companies. The net proceeds of the offering will be used to accelerate the development and distribution of Ei’s medicinal and functional mushroom lines.
David Nikzad, Founder and CEO of Ei.Ventures, notes: “We are so committed to the unaccredited investor that we are pursuing an A regulation offer.” Adding: “As I was fortunate enough to invest early in many companies like Airbnb, Betterment and Vidyard, and three crowdfunding platforms (WeFunder, RealCrowd, Republic), I am really passionate about democratizing investment opportunities so that any investor can benefit from it. the rewards and risk of investing early in game-changing companies. “
As part of their research and development of natural psychedelic compounds, EI recently announced via Forbes that they have teamed up with the Tioga Research transdermal delivery center to develop a transdermal patch for prolonged delivery of psilocin, the active ingredient in psilocybin mushrooms, for mental health applications.
The company believes that this announcement, along with the growing interest in psychedelic medicine in the field of mental health, and a growing wave of medicalization, decriminalization and legalization of psychedelic mushrooms are sparking interest across the board. psychedelic medicine, and Ei.Ventures in particular.
On Monday, October 4, Seattle City Council voted to decriminalize the non-commercial possession and cultivation of many psychedelics, including mushrooms, for “religious, spiritual, healing or personal growth practices.” Council members adopted the resolution unanimously, with a 9-0 vote. This makes Seattle the largest city in the United States to decriminalize psychedelic plants and mushrooms.
As part of Ei’s dual track approach, they plan to launch their MANA fungus functional nutraceutical line in early 2022. They are creating proprietary formulations using a unique formulation process for improved bioavailability and efficacy. These products target cognition and the immune system; energy, vitality, mood, sleep and weight loss; mental and physical optimization for microdosers; nootropics or Smart Drugs; and joint and muscle pain.
You can find the Ei.Ventures Settlement A Offer Circular here https://www.sec.gov/Archives/edgar/data/1823182/000110465921096304/tm2123436d1—253g2.htm. For more information on Ei.Ventures, visit https://invest.ei.ventures/. For media inquiries, please contact Susan von Seggern at [email protected] or 213-840-0077.
Forward-looking statements: Certain information contained in this presentation, as well as all supplements and any other information that may be provided to potential investors by the Company in this regard, contains “forward-looking statements” and “forward-looking information” within the meaning of applicable United States provisions. . State securities legislation (referred to herein as forward-looking statements). Except for statements of historical fact, certain information contained in this document constitutes forward-looking statements which include, but are not limited to, statements relating to activities, events or developments that Ei.Ventures expects. or anticipates that they will or may occur in the future, statements related to the The objectives and goals of the company’s business strategy and management’s assessment of future plans and operations which are based on current internal expectations, estimates, projections, assumptions and beliefs, which may prove to be incorrect. Forward-looking statements can often be identified by the use of words such as “could”, “will”, “could”, “could”, “anticipate”, “believe”, expect “,” estimate “,” budget “,” planned “,” plans “,” planned “,” forecasts “,” objectives “and similar expressions or their negative aspects. Forward-looking statements are neither historical facts nor guarantees of future performance. Forward-looking statements are based on a number of factors and assumptions made by management and believed to be reasonable at the time such information is provided, and forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those expressed or implied by forward-looking statements.
View source version on businesswire.com:https://www.businesswire.com/news/home/20211019005466/en/
CONTACT: Susan von Seggern
KEYWORD: UNITED STATES NORTH AMERICA FLORIDA
INDUSTRY KEYWORD: ALTERNATIVE MEDICINE HEALTH RESEARCH PHARMACEUTICAL SCIENCE BIOTECHNOLOGY
SOURCE: Emotional intelligence companies
Copyright Business Wire 2021.
PUB: 10/19/2021 6:00 a.m. / DISC: 10/19/2021 6:02 a.m.
Copyright Business Wire 2021.